Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the β-amyloid (Aβ) deposits characteristic of this neurodegenerative disorder. “We have done many basic studies in the laboratory on microglia. Microglia activation occurs in many neurologic diseases. One of them is multiple sclerosis (MS). And it also occurs in AD,” senior author Howard Weiner told BioWorld.
Researchers have developed a rice-sized implant hat can test the effects of drugs on a patient’s brain tumor in real-time during surgery. Experts at Brigham and Women’s Hospital in Boston designed the device specifically to help test treatments in patients with brain cancers or gliomas, a type of tumor that originates in the brain or spinal cord.
Researchers at Mass General Brigham found that ChatGPT was unsuccessful in recommending cancer treatments, with 34% of responses not aligning with National Comprehensive Cancer Network guidelines.